Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

STAT3 Inhibitors in Cancer: A Comprehensive Update
Uddalak Bharadwaj, Moses M. Kasembeli, David J. Tweardy
Cancer drug discovery and develogment/Cancer drug discovery and development (2016), pp. 95-161
Closed Access | Times Cited: 19

Showing 19 citing articles:

Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 to Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution
Uddalak Bharadwaj, Moses M. Kasembeli, Prema Robinson, et al.
Pharmacological Reviews (2020) Vol. 72, Iss. 2, pp. 486-526
Open Access | Times Cited: 237
Targeting Cancer Stem Cells in Triple-Negative Breast Cancer
So‐Yeon Park, Jang‐Hyun Choi, Jeong‐Seok Nam
Cancers (2019) Vol. 11, Iss. 7, pp. 965-965
Open Access | Times Cited: 149
JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies
Bilal Rah, Rafiq A. Rather, Gh Rasool Bhat, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 132
Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice
Kwang Hwa Jung, Wonbeak Yoo, Heather L. Stevenson, et al.
Clinical Cancer Research (2017) Vol. 23, Iss. 18, pp. 5537-5546
Open Access | Times Cited: 105
Activation of STAT3 and STAT5 Signaling in Epithelial Ovarian Cancer Progression: Mechanism and Therapeutic Opportunity
Chin‐Jui Wu, Vignesh Sundararajan, Bor‐Ching Sheu, et al.
Cancers (2019) Vol. 12, Iss. 1, pp. 24-24
Open Access | Times Cited: 64
Activation of STAT3 is a key event in TLR4 signaling-mediated melanoma progression
Xiu‐Qiong Fu, Bin Liu, Yaping Wang, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 4
Open Access | Times Cited: 57
Targeting STAT3 in Cancer with Nucleotide Therapeutics
Yue-Ting Kara Lau, Malini Ramaiyer, Daniel E. Johnson, et al.
Cancers (2019) Vol. 11, Iss. 11, pp. 1681-1681
Open Access | Times Cited: 46
STAT3 and p53: Dual Target for Cancer Therapy
Thu‐Huyen Pham, Hyo‐Min Park, Jinju Kim, et al.
Biomedicines (2020) Vol. 8, Iss. 12, pp. 637-637
Open Access | Times Cited: 41
TTI-101: A competitive inhibitor of STAT3 that spares oxidative phosphorylation and reverses mechanical allodynia in mouse models of neuropathic pain
Moses M. Kasembeli, Pooja Singhmar, Jiacheng Ma, et al.
Biochemical Pharmacology (2021) Vol. 192, pp. 114688-114688
Open Access | Times Cited: 28
Molecular crosstalk between MUC1 and STAT3 influences the anti-proliferative effect of Napabucasin in epithelial cancers
Mukulika Bose, Alexa Sanders, A Handa, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 4
Formulation of Stattic as STAT3 inhibitor in nanostructured lipid carriers (NLCs) enhances efficacy of doxorubicin in melanoma cancer cells
Jamal Mohammadian, Shiva Mahmoudi, Pirouz Pourmohammad, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2020) Vol. 393, Iss. 12, pp. 2315-2323
Closed Access | Times Cited: 25
Deformable liposomal codelivery of vorinostat and simvastatin promotes antitumor responses through remodeling tumor microenvironment
Bin Tu, Yang He, Binfan Chen, et al.
Biomaterials Science (2020) Vol. 8, Iss. 24, pp. 7166-7176
Closed Access | Times Cited: 18
PIM1/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer
Sutapa Mahata, Pranab Kumar Sahoo, Ranita Pal, et al.
Medical Oncology (2022) Vol. 39, Iss. 7
Closed Access | Times Cited: 11
A decision process for drug discovery in retinoblastoma
María Belén Cancela, Santiago Zugbi, Ursula Winter, et al.
Investigational New Drugs (2020) Vol. 39, Iss. 2, pp. 426-441
Open Access | Times Cited: 16
Novel STAT3 small-molecule inhibitors identified by structure-based virtual ligand screening incorporating SH2 domain flexibility
Ren Kong, Uddalak Bharadwaj, T. Kris Eckols, et al.
Pharmacological Research (2021) Vol. 169, pp. 105637-105637
Open Access | Times Cited: 11
Revisiting the role of endogenous STAT3 in HPV‐positive cervical cancer cells
Tobias D. Strobel, Maria Weber, Nora Heber, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 11
Open Access | Times Cited: 4
Improved delivery and antimetastatic effects of Stattic by self-assembled amphiphilic pendant-dendron copolymer micelles in breast cancer cell lines
Yee Chu Kwa, Yuen Fen Tan, Yiing Yee Foo, et al.
Journal of Drug Delivery Science and Technology (2020) Vol. 59, pp. 101905-101905
Closed Access | Times Cited: 6
Natural bioactive compounds and STAT3 against hepatocellular carcinoma: An update
Suryaa Manoharan, Shreejit Saha, Krishnasanthiya Murugesan, et al.
Life Sciences (2023) Vol. 337, pp. 122351-122351
Closed Access | Times Cited: 2
Data from Multifunctional Effects of a Small-Molecule STAT3 Inhibitor on NASH and Hepatocellular Carcinoma in Mice
Kwang Hwa Jung, Wonbeak Yoo, Heather L. Stevenson, et al.
(2023)
Open Access
Page 1

Scroll to top